ACRO's CRO Forum Will Liaise with TransCelerate
The Association of Clinical Research Organizations held its inaugural meeting of the CRO Forum. The Forum was established in October 2014 as the primary vehicle for interaction between the CRO industry and TransCelerate BioPharma.
The Association of Clinical Research Organizations held its inaugural meeting of the CRO Forum. The Forum was established in October 2014 as the primary vehicle for interaction between the CRO industry and TransCelerate BioPharma. ACRO and TransCelerate have mutually agreed to initially establish liaison relationships between four TransCelerate workstreams: risk-based monitoring; shared site qualification and training; common protocol template; and quality management system.
The Forum elected as its first Chairman Dr. Alan Metz, Senior Vice President and Managing Director, Strategic Partnerships, at Quintiles. As Vice Chair, the Forum elected Amy Kissam, Executive Director, Global Operational Management, at INC Research. In addition, the CRO Forum selected senior subject matter experts to serve as liaisons to each of the workstreams, and will be supported by working groups consisting of subject matter experts from across the Forum membership.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
